ea0065oc4.4 | Thyroid | SFEBES2019
Sovetkina Alina
, Nicholas Richard
, Malik Omar
, Tona Francesca
, Dorsey Rachel
, Scalfari Antonio
, Rigoni Eleonora
, Nandoskar Ashwini
, Singh-Curry Victoria
, Martin Niamh
Background: Alemtuzumab is an anti-CD52 monoclonal antibody used in the treatment of relapsing-remitting multiple sclerosis (MS). Between 20 and 40% of Alemtuzumab-treated MS patients develop autoimmune thyroid disease (AITD) as a side effect. It is currently unknown whether development of AITD correlates with MS disease activity following Alemtuzumab treatment.Aims: To characterise the types and frequency of AITD that MS patients develop following Alemt...